Akèy › Sipwa › North Carolina › Charlotte
Etid klinik pou Sipwa nan Charlotte, NC
15 etid pou Sipwa ap chèche patisipan nan sit nan ak bò kote Charlotte (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Ap rekriteFaz 3
- Novant Health Heart and Vascular Institute, Charlotte
- Monroe Biomedical Research, Monroe · 24 mi lwen
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 2
- Monroe Biomedical Research /ID# 282009, Monroe · 24 mi lwen
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Ap rekriteFaz 3
- Monroe Biomedical Research, Monroe · 24 mi lwen
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Monroe Biomedical Research, Monroe · 24 mi lwen
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Ap rekriteFaz 3
- Monroe Biomedical Research, Monroe · 24 mi lwen
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Ap rekriteFaz 3
- Research Site, Monroe · 24 mi lwen
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Ap rekriteFaz 3
- AURORA-2 Clinical Site, Charlotte
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Ap rekriteFaz 3
- AURORA-1 Clinical Site, Charlotte
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Ap rekriteFaz 3Volontè an sante akeyi
- ACCOMPLISH-2 Research Site, Charlotte
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Ap rekriteFaz 2
- Monroe Biomedical Research, Monroe · 24 mi lwen
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Ap rekriteFaz 4
- Onsite Clinical Solutions - Huntersville, Huntersville · 13 mi lwen
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Ap rekriteFaz 3
- Kailera Clinical Site, Monroe · 24 mi lwen
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Ap rekriteFaz 3
- ACCOMPLISH-1 Research Site, Charlotte
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Ap rekriteFaz 1
- Monroe Biomedical Research, LLC, Monroe · 24 mi lwen
A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
Ap rekriteFaz 2
- Monroe Biomedical Research, Monroe · 24 mi lwen
Etid Sipwa nan lòt vil
- San Antonio, TX34 etid
- Houston, TX33 etid
- Chicago, IL29 etid
- Orlando, FL27 etid
- Las Vegas, NV23 etid
- Miami, FL23 etid
- Dallas, TX20 etid
- Atlanta, GA20 etid
- New York City, NY19 etid
- Jacksonville, FL19 etid
- Washington, DC19 etid
- Austin, TX18 etid
Lòt etid nan Charlotte
- Kansè (tout kalite)27 etid
- Kansè nan tete22 etid
- Myelom Miltip21 etid
- Kansè Poumon ki pa ti selil19 etid
- Leksemi mieloïd egi16 etid
- Obèsite16 etid
- Kansè kolorektal13 etid
- Kansè ovè12 etid
- Ensifizyans kadyak11 etid
- Kansè Metastatik11 etid
- Karsinòm selil skuamèz tèt ak kou10 etid
- BPCO9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.